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Abstract: Plastics have found widespread use in the fields of cosmetic, engineering, and medical 
sciences due to their wide-ranging mechanical and physical properties, as well as suitability in 
biomedical applications. However, in the light of the environmental cost of further upscaling 
current methods of synthesizing many plastics, work has recently focused on the manufacture of 
these polymers using biological methods (often bacterial fermentation), which brings with them the 
advantages of both low temperature synthesis and a reduced reliance on potentially toxic and non-
eco-friendly compounds. This can be seen as a boon in the biomaterials industry, where there is a 
need for highly bespoke, biocompatible, processable polymers with unique biological properties, 
for the regeneration and replacement of a large number of tissue types, following disease. However, 
barriers still remain to the mass-production of some of these polymers, necessitating new research. 
This review attempts a critical analysis of the contemporary literature concerning the use of a 
number of bacteria-derived polymers in the context of biomedical applications, including the 
biosynthetic pathways and organisms involved, as well as the challenges surrounding their mass 
production. This review will also consider the unique properties of these bacteria-derived polymers, 
contributing to bioactivity, including antibacterial properties, oxygen permittivity, and properties 
pertaining to cell adhesion, proliferation, and differentiation. Finally, the review will select notable 
examples in literature to indicate future directions, should the aforementioned barriers be 
addressed, as well as improvements to current bacterial fermentation methods that could help to 
address these barriers. 
Keywords: bacteria; biopolymer; biosynthesis; biomaterial; regenerative medicine; tissue 
engineering; drug delivery; biodegradable polymers; polymer science; hydrogel 
 
1. Introduction 
Plastics have become incredibly important to our modern world. In 2019, it was 
estimated that globally, more than 350 million tons of plastic was generated in a year [1]. 
This success story is due in part to the incredible versatility of plastics, where the wide 
range of tuneable properties, generally reduced density, and variety of polymer classes 
have allowed for the replacement of metals and ceramics in all areas, from aerospace 
engineering to the biomedical arena [2,3]. 
Nowhere is this set of properties more useful than in the field of biomaterials. Plastics 
as a group contain valuable properties which make them ideal for use, both in medical 
devices and as in vivo implants for the treatment of pathological conditions. Early 
polymers used as biomaterials were hailed as being “bio-inert”, a property that allows the 
material to carry out its function without a widespread immune response and subsequent 
rejection [4]. Recently though, the onus has been on “bioactive” polymers, materials 
which actively interact with in vivo systems to bring about therapeutic change [5]. These 
may include measures to prevent bacterial adhesion or fouling, such as hydrophilic PEG 
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coatings [6,7], immunoisolation polymers to protect therapeutic agents from the immune 
system [8], and biomodulatory polymers that may increase both cell differentiation and 
growth through chemical factor incorporation and advanced manufacturing techniques 
like electrospinning and additive manufacturing [9,10]. 
However, while purely synthetic polymer production has been incredibly successful 
in biomaterials science, there are of course notable disadvantages. Whilst the incredible 
longevity and durability of polymers has been a boon to multiple respective industries, 
the formation and subsequent concentration of microplastics in ecosystems worldwide 
has been a major concern of both conservationists and materials scientists alike [11]. 
Additionally, the mass-manufacture, usage, and disposal of commonly used polymers 
generates harmful emissions such as heavy metals, greenhouse gasses, and aerosolised 
microplastics [12–14]. Despite the development of international public awareness 
strategies to reduce polymer use globally, there is a clear need in the biomaterials sector 
for mass-production of polymers that retain or improve on current bioactive properties 
and reducing the environmental cost. One proposed solution is through the use of 
bacterial fermentation, a process by which naturally occurring or genetically engineered 
bacteria are used to produce polymers historically only available by synthetic pathways 
[15]. This technique holds various advantages over the previous chemical synthetic 
processes, including (generally) lower temperatures and pressures, enantiomeric 
selectivity and a wide manufacturing variety of biodegradable polymers, many of which 
are degradable or bioresorbable in physiological conditions [16–19]. Furthermore, even 
though many polymers cannot be currently synthesised by bacteria, the relatively simple 
molecules such as lactic acid that often make up the feedstock allow for further integration 
of less energy-intensive manufacturing methods in the polymer supply chain [20–22]. 
Finally, some polymers (such as the biomedically significant polyhydroxyalkanoates) can 
only be produced by biochemical processes [23]. This review will discuss the state of the 
art of concepts surrounding the manufacture and use of multiple bacteria-derived 
polymers in biomedical applications. 
2. The History, Contemporary Status, and Future Applications of  
Bacteria-Derived Polymers 
In this section, the materials comprising the class of novel bacteria-derived polymers 
including their classification, properties (biological, physical and chemical), current 
production processes (including subsequent modification), and current research in a 
biomedical context will be reviewed. Contemporary research will be highlighted to 
suggest future work, including methods to limit undesirable properties and exploring 
their potential for in vivo and clinical use. 
2.1. Polysaccharides 
Given that polysaccharides make up a large portion of bacterial synthesis, it follows 
that a large number of this group of molecules can be derived from bacteria. This section 
explores polysaccharides, molecules which in their structure include extensive glycosidic 
linkages of constituent sugar units. They present as products of metabolic processes for 
any organism, and can also be commonly derived from bacterial fermentation [24]. 
2.1.1. Dextran 
Consisting of α-D-glucopyranose subunits (Figure 1). Dextran is an 
exopolysaccharide with mostly α-1,6 glycosidic bonds (though smaller numbers of 
branching α-1,3, α-1,2 and α-1,4 bonds are present) [25,26]. Dextran utilization is widely 
recognized in food [27–29], cosmetic [26], and medicine [25]. Louis Pasteur first 
discovered dextran in 1861 from a viscous fermentation of wine [30], and later identified 
it via the chemical analysis of the product responsible for sucrose sugar syrup gelation 
[31]. The dextrorotatory nature of dextran inspired the nomenclature [32]. Several 
Polymers 2021, 13, 1081 3 of 48 
 
 
extensive dextran characterization studies carried out on dextran produced by Leuconostoc 
pseudomesenteroides XG5 [33], Leuconostoc mesenteroides AA1 [34], and Leuconostoc citreum 
B2 [35] confirmed its high-water retention capacity, which can allow it to act as a 
thickening agent, and potentially as a hydrocolloid and stabilizer agent [33]. 
 
Figure 1. Molecular structure of dextran. 
Dextran Synthesis and Properties 
Dextran is soluble in water, methyl sulphoxide, formamide, ethylene glycol, and 
glycerol [36], and barely reactive in mild acidic or basic environments [37]. The degree of 
branching in dextran depends on the lactic acid bacterial strain, with greater linearity 
indicating improved solubility in water [35]. For instance, dextran produced by L. citreum 
has 75% linear polysaccharide conformation [35], compared to the 95% of L. mesenteroides 
[38]; the latter therefore exhibits higher water solubility. On the other hand, the 
availability of a large number of hydroxyl groups within the glucose subunits opens up 
opportunities to consider dextran as a tailorable material in creating a number of desirable 
functionalisation [37,39]. 
Dextran was the first commercialized exopolysaccharide that The Food and Drug 
Administration (FDA) considered as “Generally Regarded as Safe (GRAS)”, which 
requires no labelling when incorporated in food products [28]. The mechanisms of its 
production are also known. The commercial dextran-producing bacterium L. mesenteroides 
does so by secreting dextransucrase enzymes that hydrolyse sucrose in the dextran 
cellular synthesis [28,40,41]. This however, is variable, with the molecular weight of the 
resulting dextran being influenced by the strain of the microbial producer [34]. Besides 
Leuconostoc, an array of other bacterial genera including Weisella [42,43], Pediococcus [44], 
and Lactobacillus [45] can produce dextran [46]. The extracellular glucosyltransferase 
enzyme catalyses transfer of D-glucopyranosyl residues from sucrose to dextran, resulting 
in the production of fructose as a by-product [32,43]. The glucosyltransferase enzyme 
production is mainly induced by the presence of sucrose in the media, instead of 
constitutive production (except for the Streptococcus species) [47,48]. The feedstock used 
for dextran production can include a wide array of sustainable elements, with some 
studies utilising sugarcane waste, raw sucrose, and sugarcane molasses to increase 
dextran production two-fold [49]. 
Dextran as a Potential Biomaterial 
Despite being widely recognized and produced mainly within the food industry, 
dextran is also known for its suitability for biomedical applications, due to its relative 
biocompatibility and biodegradability. Incorporation of dextran in drug delivery systems 
takes advantage of its structural integrity in forming hydrogels. Pescosolido et al. [50] 
developed dextran-hydroxyethyl methacrylate with an alginate-based hydrogel system, 
which was found to have suitable flow properties that assisted injection for drug intake, 
and preserved dextran’s highly tuneable degradation rates (15–180 days). Pacelli et al. [51] 
used dextran-polyethene glycol cryogels to produce scaffolds exhibiting 
cytocompatibility with controlled vitamin B12 release profiles. Additionally, dextran-
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drug conjugates such as dextran-flurbiprofen and dextran-suprofen resulted in better 
therapeutic effects by enhancing their analgesic and antipyretic properties whilst 
reducing their constituent drug’s ulcerogenic effect [52]. Valproic acid-dextran conjugates 
have been shown to possess anticonvulsant properties as well as reducing the hepatocyte-
toxicity and ulcerogenic effect of the epilepsy drug [53]. In another work of dextran-based 
functionalised material by Cai et al. [54], dextran was grafted with poly-ε-caprolactone in 
a novel hydrogel, aiming for enhanced mechanical properties with promising 
degradability in tissue engineering applications. 
Dextran is a promising potential drug carrier material and has been found to have 
many advantages in targeting therapeutic approaches for several organs [37]. This 
degradability is attractive in colon-centered therapies, given the availability of dextranase-
secreting saccharolytic bacteroides microflora within the intestine [55]. In this scenario, 
dextran is paired with therapeutic agents (where oral intake was previously impossible) 
synthetic hydrocortisone [56] and insulin [57]. The drugs are then released within the 
alimentary tract via gut bacteria-mediated enzymatic hydrolysis. Approaches in liver-
targeting drugs have also been successful with dextran-based nanoparticles displaying 
low toxicity and multifunctionality (most notably in carrying nucleic acids) [58]. These 
approaches enable further endeavors towards the development of an enhanced targeted 
therapeutic vehicle by taking advantage of the chemistry of dextran towards human 
physiological responses. Other applications of dextran include their use as an 
antithrombotic agent in blood, as a volume expander and viscosity reducer for combating 
anaemia, as well as a haemodiluent for blood rheological rectification [59]. Based on the 
available literature, dextran is deemed to have a number of potential roles in the advanced 
biomedical field, mainly in drug delivery application in a number of target areas, whilst 
careful conjugation methods enable the development of a variety of dextran-based drug 
delivery materials. 
2.1.2. Glycogen 
Glycogen Properties and Current Research 
Glycogen is a homopolysaccharide, made of multiple chains of glucose molecules, 
held together by both α-1,4 glycosidic bonds, and α-1,6 glycosidic bonds, providing linear 
and branched components that allows for efficient packing [60]. In this regard, glycogen 
is similar to plant-derived starch and cellulose, with the exceptions of its source, aggregate 
geometry, and linkage type [61,62]. Nevertheless, glycogen is vital in mammals, acting as 
an energy store and a homeostatic tool for the regulation of blood sugar concentrations in 
multiple tissue types (Figure 2) [63,64]. Although bacterial cellulose has been widely 
explored as a bacteria-derived polymer, glycogen’s potential therapeutic roles as a bulk 
material remain relatively unexplored [65–67]. 
  








Figure 2. (a) The structure of glycogen, (b) biosynthetic pathway, and (c) regulatory pathway for glycogen accumulation 
in bacterial systems. Used with permission from Cifuente et al. [68]. © 2021 The Author(s). Published by Elsevier B.V. 
The structure of glycogen comprises of branched chains of glucose molecules. Given 
its shared energy storage role between multiple kingdoms, glycogen is unsurprisingly 
found within the human body [69]. Moreover, its presence in healthy tissue assumes the 
body is able to break glycogen down. Under the homeostatic action of glucagon (produced 
by the islets of Langerhans), glycogen undergoes several enzymatic steps involving the 
breakdown of the α-1,4 and α-1,6 glycosidic bonds comprising glycogen’s microstructure 
[70–72]. Conversely, whilst this process occurs as part of healthy haemostatic function, 
implanted glycogen has been shown to induce some immune effects in vivo; indeed, 
glycogen injection has long been used to induce activation of polymorphonuclear 
neutrophils, possibly due to perceived liver hepatocyte damage [73,74]. However, given 
that glycogen degradation is regulated by homeostatic metabolic function in the human 
body, it is possible that small, if not bulk quantities of implantable material may be 
accepted in vivo. 
In addition to non-toxic breakdown products, glycogen possesses excellent chemical 
properties for use as a biomaterial. As mentioned previously, glycogen possesses a 
“hyperbranched structure”, capable of packing a large quantity of glucose entities in a 
relatively small space. However, the branching crosslinks resemble polymers used in the 
manufacture of hydrogels, water-swollen, highly crosslinked polymer networks, common 
in the biomaterial and tissue engineering research [75–77]. Work has already been 
undertaken using this approach; Patra et al. [78] successfully crosslinked glycogen and N-
isopropylacrylamide with the linker molecule EGDMA, to produce a stable hydrogel, 
capable of both supporting and significantly accelerating mesenchymal stem cell 
proliferation. [79] followed up this work in 2020, showing that crosslink modification of a 
biopolymer containing glycogen and glycine changed both its swelling characteristics and 
mechanical properties. This has far ranging impacts for the usefulness of glycogen-based 
biomaterials for tissue engineering, especially considering that the substrate mechanical 
properties often determine proliferation depending on cell types, response to external 
chemical factors and even determining cell differentiation and phenotype [80–82]. Some 
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studies have suggested the use of glycogen as a cross-linking agent. Zhang et al. [83] 
postulated that the branched structure could allow for multiple functional-molecule 
binding sites in three dimensions, testing this hypothesis through the generation of 
collagen-hydroxyapatite hydrogels, improving mesenchymal stem cell-osteoblast 
differentiation. This was achieved by decorating glycogen with guanido (a functional 
molecule found on the side chain of arginine) oxidising the resultant molecule to produce 
microspheres of CHO-Gly-guanido (Figure 3). Although glycogen in both bulk and 
hydrogel form has not been used extensively for clinical applications, hydrogels have 
often been touted as a candidate for improved drug delivery applications, with multiple 
clinical trials already underway [84–86]. Research has confirmed glycogen’s usefulness as 
a potential drug delivery device. Indeed, Patra et al. [78] demonstrated both 97% 2-month 
stability and controlled release capacity of loaded ornidazole (an antibiotic) from glycogen 
hydrogels. Moreover, Han et al. [87] decorated glycogen nanostructures with β-galactose, 
allowing, through Asiologlycoprotein (ASGPR)-galactose binding, to target liver cancer 
cells with limited uptake from other organs in a mouse model. Whilst this does not prove 
efficacy in humans, it is certainly an important step in demonstrating effective drug 
delivery systems using bacteria-derived polymers. 
 
Figure 3. The process of using the flexible crosslinking nature of glycogen to produce a 
nanohydroxyapatite/collagen scaffold for the differentiation of bone and cartilage tissue. 
Reprinted with permission from Zhang et al. [83]. Copyright © American Chemical Society. 
Despite its relative biocompatibility there is little literature describing the chemical 
and physical properties of glycogen as a functional material. This may be due to its 
relatively poor tensile strength. At a tensile strength of 0.128 MPa, Hussain et al. [88] found 
their glycogen-derived hydrogel to have an average value amongst the group, and 
certainly inferior to other biopolymer-derived hydrogels like chitosan and gelatine, as 
collated in a review by Hua et al. [88–91]. However, the glycogen-derived hydrogel 
demonstrated superior elongation at fracture, reaching 810% strain. Moreover, Hussain et 
al. [88] showed a strong correlation between the hydrogen bonding ability of each material 
(following cleavage and exposure of the functional –OH groups) and both elongation at 
fracture and self-healing efficiency, with the 1:1 glycogen/PVA hydrogel achieving 96% 
shape recovery, following cutting with a knife. This indicates that the addition of glycogen 
to existing hydrogels may confer elongation properties for tissues under continuous 
flexion (heart, muscle, bone etc.) (Figure 3), whilst allowing for a self-healing capacity 
following damage that may reduce follow up procedures following implant failure [92–
94]. 
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Concepts, Advantages and Limitations of Glycogen Production by  
Bacterial Fermentation 
While the above properties of glycogen are excellent, most of the polymer obtained 
for research has been derived from enzymatic or synthetic laboratory manufacturing 
pathways. However, bacteria-derived glycogen is known, with nitrogen, carbon, salt, 
phosphate, sulphur and H+ ions, all contributing to glycogen biosynthesis in prokaryotic 
organisms [95–98], often during the stationary phase of growth [99]. These conditions are 
tabulated in a review by Preiss [99], who further tabulates a number of bacteria from 
which glycogen accumulation has been documented, including multiple strains of the 
genera Streptomyces, Rhizobium and Methanococcus, as well as multiple strains of the 
common opportunistic pathogens of genera Streptococcus, Enterobacter and Escherichia 
[100–105]. Since then, multiple other genera have been documented to produce glycogen, 
including Synechococcus, Micropruina, and Candidatus [106–108]. Given the number of 
genera exhibiting a potential for glycogen accumulation, the metabolic pathways involved 
in this process is fairly common to all. Indeed, in their paper, Preiss and Romeo [109] note 
that most glycogen accumulating bacteria known at time of publication operate using a 
highly conserved set of enzymes, including an ADP-glucose phosphorylase, glycogen 
synthase, and glycogen branching enzymes. 
Despite the large number of described strains exhibiting the same biosynthetic, the 
literature on industrial-scale bacterial glycogen synthesis is remarkably sparse, which 
may explain why its applications have yet to be as widely reported as compared to other 
bacteria-derived polymers, such as the Polyhydroxyalkanoates. Nevertheless, it has been 
attempted. In efforts to manufacture feedstock for biofuel production, Aikawa et al. [110] 
cultured a euryhaline cyanobacteria (Synechococcus strain PC7002) for seven days, 
producing a maximum 3.5 g of glycogen from 500 mL of their “optimally conditioned” 
media. Although a step in the right direction, inefficiencies were noted, due in part to the 
fact that glycogen accumulates intracellularly, necessitating the disruption and 
subsequent lysis of the cell, compared to other extracellularly secreted polymers like 
gamma-PGA, which may be extracted with techniques tailored to minimize cell 
disruption such as centrifugation [111,112]. Given Aikawa et al. [110] lyophilized their 
microorganisms after seven days, an alternative would be selection of strains that secrete 
extracellular glycogen. While it is known that multiple Pseudomonas species produce 
copious quantities of polysaccharide biofilm under quorum sensing conditions, Sambou 
et al. [113] first detected “glycogen like capsules” secreted from Mycobacterium 
tuberculosis isolates. [114] produced the first evidence of non-pathogen-derived 
extracellular glycogen secretion in Pseudomonas fluorescens isolates [113–115]. Whilst these 
results may provide avenues of research for extracellular bacteria-derived glycogen 
extraction, more research may be needed to confirm other species of extracellular 
glycogen accumulators, as well as determining the genes and mechanisms responsible for 
extracellular glycogen secretion, in order to fully achieve industrial bacterial glycogen 
manufacture. 
2.1.3. Alginate 
Alginates are natural unbranched exopolysaccharides, obtained mainly from 
seaweeds and bacteria, with the major source of prokaryote-derived alginate coming from 
the genera Pseudomonas and Azotobacter. Alginic salt can also be derived from this 
compound and is given the general term, algin [116]. It was discovered by E.C.C. Stanford 
in 1883 while working on dietary needs improvement methods [117]. Stanford was able 
to precipitate out a mucus-like substance called algin using sodium carbonate with further 
acidification from kelp [15]. The mucilaginous algin displayed both colloidal and gelation 
properties, showing a high level of viscosity on the addition of salts like sodium and 
potassium [118]. Krefting received a patent over algin purification in 1896, before its 
recognition and GRAS (Generally Recognized As Safe) classification by the FDA [119]. 




Structure, Biosynthesis and Modifications 
The basic structure of alginate consists of β-D-mannuronic acid and the C5 epimer α-
L-guluronic acid. These two uronic acids are linked by 1,4-glycosidic bonds (Figure 4). 
Alginate has been produced in both hetero and homopolymer configurations, with the 
former being the naturally occurring form (the latter can still be produced from the early 
stage of polymerization by manipulating the gene expression of the bacteria to inactivate 







Figure 4. Structure of alginate (a) monomer, (b) chain conformation, and (c) distribution [120]. 
The biosynthetic pathway, as it is best understood in Pseudomonas aeruginosa, is 
encoded by a single operon with 12 genes [116], starting with the synthesis of the active 
precursor guanosine-diphosphate (GDP)-mannuronic acid in cytosol. This is followed by 
polymerization by Alg8 polymerase-mediated transfer of sugar molecules from the donor 
to the growing acceptor molecule chain with the Alg8 polymerase (Figure 5). Finally, the 
periplasmic proteins help in modification and the product is exported [118]. 




Figure 5. Schematic representation of biosynthesis of alginate in P. aeruginosa. Modified with 
permission from Schmid et al. [121]. 
As with any material of natural origin, the composition of the different components 
present in the polymer can vary significantly, from number to length of the monomer 
units. It is this composition that determines the physical and chemical properties of 
alginates. The factors that influence the mass and chain length of the material are the 
source, growing medium, and polymerisation conditions provided. Alginates extracted 
from seaweed have a high guluronic acid content compared to that produced from P. 
aeruginosa. Additionally, the intrinsic viscoelasticity of alginate depends on the decreasing 
flexibility of the constituents (guluronic acid-mannuronic acid > mannuronic acid-
mannuronic acid > guluronic acid-guluronic acid) of alginate [122,123]. 
To form crosslinks, alginates can bind with divalent cations depending on the affinity 
of the ions allowing them to form a stable hydrogel or scaffolds [124]. The efficiency of the 
crosslinks is based on the selectivity, interaction, and affinity of the divalent cations with 
alginates, from lowest (Mg2+) to highest (Pb2+), giving the resulting product mechanical 
properties resembling stiffer tissues. The relative ratio of the constituents and their cations 
also play an important role in determining the physical and biological properties of the 
hydrogel. Such unique material properties have led to its application in agriculture, food, 
textile, cosmetic, and pharmaceutical/biomedical industries [116]. 
In order to enhance alginate’s properties, improvements and modifications have 
been made to the molecule. Numerous methods for chemical and physical modifications 
(ionic, covalent crosslinking, free radical reaction) have been developed to enhance their 
bioactivity and physical properties [125]. One such modification is the alteration of the 
two components through enzymes. Campa et al. [126] focused on isolating and 
recombining mannuronan C-5 epimerases expressed in wild-type Azotobacter vinelandii 
into Escherichia coli for enzymatic epimerisation that converts mannuronic acid residues 
into guluronic acid. Other enzymatic modifications include depolymerisation processes 
to isolate oligosaccharides from the alginate backbone. This can also be done by acid 
hydrolysis [127]. Additionally, acetylation, copolymerization reactions, and oxidation are 
employed to perform chemical modifications on hydroxyl groups among many others, 
while esterification and amidation modify the carboxylic groups [128]. On covalently 
attaching alkyl or aromatic groups to the backbone, solubility parameters can be altered, 
which will further affect resorption in the physiological system. As a result, a lot of 
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research is being carried out to produce alginate derivatives, recognising their potential, 
especially in biomedical applications [129,130]. 
Potential Applications of Alginate in Biomedicine 
The progress in the synthesis, processing, and modification of alginate has opened 
doors in biomedicine. Alginates are typically used in drug, protein and other bioactive 
molecule delivery systems as the release profile can be regulated to a very fast release or 
a prolonged one due to their porosity and gel formulation [131]. Multiple drugs with 
different release patterns were observed with alginates, non-interactive methotrexate 
diffused swiftly while a covalently attached doxorubicin only released after chemical 
hydrolysis [132]. Alginate in combination with chitosan has been explored widely, mainly 
because of its unique swelling behaviour. Few examples are in colonic and gastric drug 
delivery, where a sustained release and exceptional swelling degree was observed [133]. 
Divalent calcium ion modified alginate hydrogel as a carrier against Helicobacter pylori 
infection allowed for specific interaction and release in the site of infection [134]. Reports 
suggest that encapsulated proteins like lysosomes in ionically crosslinked alginate spheres 
can link to the matrix physically, which helps in a more sustained release. Alginate gel 
and their control over the release of angiogenic molecules have gained much attention 
due to their spatiotemporal control in delivery that aids in neovascularisation [135]. 
Since the properties of alginate facilitate appropriate wound moisture retention and 
wound healing, they are excellent candidates in dressing applications. There are a variety 
of commercially available alginate dressing like Algicell™, AlgiSite M™, Comfeel Plus™, 
Kaltostat™, Sorbsan™, and Tegagen™ [136]. Rabbany et al. [136] used Stromal Cell-
Derived factor 1 (SDF-1) to induce accelerated recovery of the epithelial wound in rat and 
pig models. The cell-adhesive and degradation behaviour are the main features that allow 
alginate to be used in a wide range of tissue engineering applications. Alginate has been 
used successfully as a minimally invasive material in bone tissue engineering to deliver 
cells, osteoinductive factors, and other molecules like bone morphogenic proteins [137]. 
In addition, alginate with calcium sulphate pre-shaped 3D cartilage had an elastic 
modulus almost similar to that of native cartilage and retained shape up to 30 weeks [138]. 
In liver tissue engineering, alginate showed efficient seeding capacity of hepatocytes 
while maintaining functional viability because of their porous, interconnected, and 
hydrophilic nature [139]. Alginate gels could regenerate axons from a transected nerve 
stump restoring the nerve gap with no major inflammatory responses [140]. The track 
record of the material suggests that alginate has the potential and utility for a number of 
wide-ranging biomedical applications for a number of different tissue types. 
2.1.4. Hyaluronic Acid 
Unlike glycogen, where endogenous granules of substance are not found within the 
human body and alginate, which is not naturally produced nor hosted by the human 
body, hyaluronic acid (HA) naturally occurs in mammals, having first been isolated from 
the “vitreous humour” of the bovine eye by Meyer and Palmer [141] in 1934. Since then, 
sustained analysis of the polymer has revealed unusual chemical and physical properties, 
making HA both an easily modifiable biomaterial for multiple clinical roles (Figure 6) and 
a well-known polymer produced using bacterial fermentation. 
  




Figure 6. The popular modifications and potential biomedical applications of hyaluronic acid. Used with permission from 
Fallacara et al. [142]. Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. 
Properties, Current and Future Clinical Usage 
Despite being a polysaccharide, HA does have some major structural differences to 
glycogen. HA is unbranched, its microstructure consisting of long parallel single chains 
of disaccharide sugars, which are themselves made up of glucuronic acid and N-acetyl-D-
glucosamine [143,144]. This arrangement of N-acetyl hexosamine and hexose-based 
disaccharides defines HA as a glycosaminoglycan (GAG), a group of molecules which 
make up a gel-like “ground substance”, resulting in the extracellular space (Figure 7). 
 
Figure 7. The backbone of the hyaluronan molecule, with the main constituents of D-glucuronic 
acid (left) connected via ester linkage to N-acetyl glucosamine (right). Reused with permission 
from Ward et al. [145]. Copyright © 2021 Elsevier Science B.V. All rights reserved. 
These constituents are partially formed from a proteoglycan core wherein chains of 
GAGs extend, the presence of sulphonated groups that (together with the carboxylic acid 
groups of N-acetyl hexosamine and hexose) attract water molecules, allowing the final 
hydrated macrostructure a degree of rigidity [146–149]. Despite HA’s fairly unique 
position amongst the GAGs of being the only member of the group not to contain sulphate 
groups, HA retains its negative carboxylic acid groups, and therefore some water 
retentive ability [143,144]. HA is also exceptionally large with molecular weight between 
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105 and 106 Dalton and is between two to four orders of magnitude heavier than the GAGs 
chondroitin sulphate or heparin [150–152]. This allows not only for more rigidity from 
HA-HA interactions, but also limits the flow of water and solutes out of the structure. 
Finally, HA has the ability to scavenge (ROS), potentially damaging radicals released via 
photolysis and as a biological defence mechanism against foreign material. Jahn et al. [153] 
noticed that this occurs mostly on glucuronic acid residues, forming (amongst others) 
gluconic and glyceryl acids. Thus, HA acts as sacrificial protection material in vivo, since 
it loses both structure and therefore function as a result of ROS attack [153]. 
These chemical properties have wide ranging impacts for the physical and therefore 
biological properties of HA, dictating polymer function in both the in vivo environment 
and in clinical applications. HA’s water retentive ability confers compressive strength to 
tissues, acting as shock absorbers, such as in cartilage [154]. Greene et al. [155] 
demonstrated this by compressing HA-containing collagen samples under HA digestion 
conditions, finding that digesting HA tended to stiffen their construct, recovering much 
less readily due as its degraded water attraction potential prevents re-swelling [151]. 
Furthermore, HA-containing hydrogel preparations encountered greater swelling rates, 
following compression, with increasing HA concentration (though the reduction in 
compressive strength with increasing HA concentration would indicate HA’s role in 
elastic recovery, rather than resistance to compressive stress) [156–158]. Clinicians use 
HA’s hygroscopicity in multiple clinical roles, including as expanding fillers for plastic 
surgery [159]. This is possible in humans because post-translational modification of 
hyaluronic acid is limited between species, allowing for HA transplantation from bovine, 
bacterial, and poultry sources with incredibly limited immune response (mostly due to 
incomplete purification) [160,161]. Degradation is controlled over seven to nine months, 
whilst degradation products have been shown to be both non-toxic and can be 
metabolised with ease. Romagnoli and Belmontesi [162] list a number of HA products 
currently used within the filler market, including the Allergan system, Qmed, and FDP. 
However, the current medical applications of HA are not limited to plastic surgery, 
with multiple clinical trials confirming HA’s ability to improve lubrication and joint 
articulation in vivo, compared to more modern methods. Raeissadat et al. [163] decreased 
Western Ontario and McMaster Universities Arthritis Index (WOMAC) score by 11.4%, 
following HA injections into the osteoarthritic knee, noting no significant difference 
between HA and ozone treatment after six months. HA also significantly reduced the 
Visual Analogue Pain Scale (VAS) score and increased American Orthopaedic Foot and 
Ankle Society (AOFAS) score of patients suffering from ankle injury after 15.3 months 
(though it is important to note that this study recommended the use of platelet-rich 
plasma injections over HA due to its higher efficacy) [163]. In vivo articulation is also 
aided by HA’s lubricative ability. Lin et al. [164] resolved the question of HA’s lubrication 
mechanism by immersing lipid layers into liquid HA solution to determine their frictional 
coefficients, finding that whilst HA was a relatively poor lubricant, its ability to complex 
with a large number of molecules allowed for complex formation with frictionally 
superior phosphatidylcholine also found in cartilage, allowing for a synergistic increase 
in lubricity. This confirmed work undertaken in indicating a synergistic partnership 
between the mucinous glycoprotein lubricin and HA for the reduction of arthritic 
potential in mouse models [165]. Whilst these studies paint the lubricative properties of 
HA in a negative light, the presence of both complex-forming molecules in humans could 
allow for in vivo complex formation if either was implanted for therapeutic purposes, 
producing better combination treatments instead of the dichotomy of the previously 
mentioned studies. 
The final avenue of research this review will discuss is HA’s protective capacity 
against both immune cells and inflammatory factor release. Harrington et al. [166] 
methacrylated HA to produce microencapsulated islet microspheres, which were able to 
induce normoglycemia for four to six weeks without immune response in induced-
diabetic mice, though its polyethene glycol diacrylate (PEGDA) counterpart was able to 
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produce similar results non-transiently (study time was 16 weeks), perhaps due to the 
swelling following implantation generating a larger barrier to oxygen diffusion. However, 
modification using collagen HA blends crosslinked with PEGDA by [167] allowed 
microencapsulation islets to survive for up to 80 weeks with little to no fibrosis, though 
the study did not mention if their blend caused more or less swelling with collagen 
addition. Whilst this is the case, further modification may allow HA to usurp alginate as 
the current go-to microencapsulation matrix. Finally, the ease of HA functionalisation has 
allowed scientists to find a use in cancer therapies. Resnick et al. [168] found that a 
common HA receptor (CD44) was overexpressed in a number of cancers, though a link 
had already been noticed by Yang et al. [169], who also determined the selectivity of over-
expressed hyaluronan-mediated motility receptor (RHAMM) in cancer [168,170]. This 
information has been expanded upon in multiple studies combining HA’s efficacious 
drug loading capability and its affinity for cancer cells to improved targeted drug delivery 
products (though the closest these treatments are to being tested in humans has been in 
xenografted human tumour tissue) [171–174]. Nevertheless, the literature certainly 
promotes HA as a contemporary and potential clinical solution to treat multiple pathology 
types, including tissue degeneration, cancer, and autoimmune disorders. 
Past, Current and Future Manufacturing of Hyaluronic Acid 
Given the identical molecule manufacture capacity of multiple organisms 
representing three kingdoms, HA (as previously mentioned) has historically been isolated 
from a number of organisms, including bovine eye, rooster wattle, or human umbilical 
tissue [160,161]. Although these sources have generally been successful, renewed scrutiny 
due to zoonotic infection and incomplete purification methods have led to renewed 
interest in bacterial fermentation as a route for the manufacturing of HA [175,176]. A 
benefit during immunoisolation is that bacterial HA as a virulence factor generates a 
physical barrier to attacking immune cells and the complement system, while reducing 
the harmful effects of cytotoxic factors, antibiotics, and ROS, reducing the immune 
system’s ability to mount an effective response [177–179]. Gunasekaran et al. [180] 
mentions the use of the capsular HA releasing system in strains of both Streptococcus and 
Pasteurella species, though the first commercial production of HA was conducted using 
isolates of Streptococcus zooepidemicus [180,181]. Recombination of HA synthases allowed 
for a reduction in streptococci-derived endotoxins resulting from fermentations, allowing 
for reduced immune responses in vivo. [182] modulated the concentrations of dissolved 
oxygen and N-acetyl glucosamine during the fermentation process; doing so allowed 
them to modify the molecular weight of the HA produced. The industrial manufacturing 
costs of HA may be significantly reduced if a proposal by Arslan and Aydogan [183] gains 
popularity: their team replaced the traditionally expensive peptone and N-acetyl 
glucosamine feedstock with sheep wool-derived peptones and molasses, finding that the 
wool peptones generated better yields compared to commercial peptones [182–185]. Li et 
al. [186] was able to use the temperature of the reaction vessel to control the molecular 
weight of their HA. It is this ability to have fine control over not only the polymer 
produced but also the microstructure that will allow scientists to manufacture and use 
HA in a biomaterial context, to tune the process to the required mechanical properties of 
the desired application. Researchers will hence be able to fully realise the true potential of 
hyaluronic acid in the fields of wound healing, tissue engineering, and cancer research. 
2.1.5. Gellan 
Structure, Composition and Classification of Gellan Gum 
Gellan gum is a high molecular weight linear extracellular polysaccharide, 
accumulating in multiple strains, including Sphingomonas elodea, Sphingomonas 
paucimobilis, and Pseudomonas elodea [187]. Approved by the USA FDA in 1992 as a food 
additive, gellan is mainly composed of a 1,3-β-D-glucose, 1,4-β-D-glucuronic acid, 1,4-β-D 
Polymers 2021, 13, 1081 14 of 48 
 
 
glucose, 1,4-α-L-rhamnose backbone in a 3:1:1 (general) relationship, respectively (Figure 
8). Acetyl group concentration defines the three types of gellan gum [188,189]. Attached 
on the glucose residue adjacent to the glucuronic unit are the acyl groups acetate and 
glycerate, forming one among the three types of gellan gum. 
 
Figure 8. The chemical structure of n repeating units in gellan gum. Reused with permission from 
Zhang et al. [190]. Copyright © 2021 Elsevier. All rights reserved. 
During the industrial fermentation process, these additional residues or groups are 
removed through hot alkaline hydrolysis, yielding a linear simple chain polymer, 
deacetylated gellan gum [191]. This structure may transition from a highly coiled to a 
double helix structure on cooling. Even after such a transition, both acetylated and 
deacetylated gellan gum are capable of gelation. The deacetylation process results in 
physical and chemical changes to the material and gel formation, depending on the degree 
of deacetylation, making the polymer less flexible, transparent, and much more thermally 
stable, otherwise soft and elastomeric [192,193]. 
Similar to the gel-forming property of xanthan gum, the presence of a cation helps 
form a stable hydrogel as the gelation process of gellan is ionotropic. Gel formulation and 
their properties are highly influenced by factors like the number of cations used and their 
chemical structure. For example, during ionic crosslinking, divalent cations like calcium 
or magnesium show higher gelation efficiency than sodium or potassium monovalent 
cations. In the former case, the chemical bonding between the carboxylate group of 
glucuronic acid molecules and the divalent cations along with the screening effect caused 
by the electrostatic repulsion among the ionized carboxylic acid groups results in the 
gelation, while in the latter, there is only the screening effect across the gellan causing 
gelation. Moreover, gellan can be a self-supporting hydrogel even in the absence of ions 
with the mere inclusion of cell culture media [194,195]. Similar to the deacetylation 
process, clarified gellan gum is formed during fermentation, heating the broth to a 
temperature of 90–95 °C. On heating, the bacterial cells are killed and protein residues are 
removed after filtration with cartridge filters. This more viscous broth is precipitated by 
isopropyl alcohol to form the third type, clarified gellan gum. This again is available in 
two types: KELCOGEL® as an industrial food product and a more refined and purified 
Gel-Gro gellan gum used in pharmaceutical and biomedical applications [187,196]. 
Biomedical Applications of Gellan 
The use of gellan in biomedical applications requires mechanical integrity and 
stability. Certain features that limit its use include (i) the lack of mechanical strength since 
it gradually dissolves under physiological conditions; (ii) inability to envelop cells due to 
rough gelation conditions. Nevertheless, such drawbacks can be addressed by material 
modifications, possible due to the presence of hydroxyl and carboxyl groups in glucuronic 
acid. Moreover, many physical modifications have been employed and improvised for 
imparting better physicochemical and biological properties [197]. 
Such modification allows for a wider range of applications of gellan and their 
derivatives in pharmacy and medicine, especially in drug delivery, gene therapy, as 
protein carriers, tissue engineering, and regenerative medicine [198]. The major 
biomedical applications of gellan include nasal, ocular, gastric pharmaceutical delivery 
systems, and tissue engineering applications. Gellan is generally used for oral 
formulations, as gels or coatings of capsules that assist in the release of the ingredients 
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like bioactive molecules or drugs with modified or sustained release profile. Floating gels 
are one of the main forms in which gellan has been used in drug delivery. In situ floating 
gels are one such form used in a variety of applications against gastric ulcers, peptic ulcers, 
rheumatic arthritis, inflammation, and allergic rhinitis. Gellan gum beads carrying 
glipizide was developed against diabetes as a hypoglycaemic agent. These beads were 
also used for the slow release of the β-blocker propranolol, for the treatment of 
hypertension. Gellan gum gels can also protect bioactive molecules from the low pH of 
the stomach [199,200]. 
Tissue engineering application of gellan is mainly owed to its biocompatibility, 
nontoxicity, easy processability, a structural similarity with glycosaminoglycans, and 
most importantly the similarity of their mechanical properties with common tissues. The 
material porosity, binding capacity, and ionic interaction with positively charged 
biomolecules and other moieties also make them an excellent material for tissue 
engineering [201]. Gellan can be fabricated into films, fibres, 3D structures, and 
lyophilized scaffolds, as well as bioprinted and modified with RGD peptide to form multi-
layered scaffolds mimicking cortical tissue [202]. Moreover, modified gellan exhibits a 
wide range of mechanical properties, with some gellan-amyloid protein nanofiber 
scaffolds reporting specific strengths comparable to steel [203]. Improved differentiation 
of adipose stem cells was observed in gellan based sponge, which was fabricated through 
freeze-drying [204]. In addition, gellan and HA has been freeze-dried to be applied as a 
scaffold implant in skin regeneration and vascularization [205]. In cartilage repair, an 
injectable form of gellan blended with stem cell and growth factor was used for knee 
repair in an animal model. Hence, it can be concluded that gellan is a viable substrate for 
a wide variety of biomedical applications and further research is required to facilitate the 
utilization of this versatile material. 
2.1.6. Xanthan 
Produced by bacteria of genus Xanthomonas, xanthan gum is a microbial high 
molecular weight exopolysaccharide discovered by Allene Rosalind Jeanes in the 1950s. 
Xanthan is an extremely important commercial polysaccharide, used as a food thickener 
or stabilizer [206] and in industrial applications, where xanthan’s thermal stability and 
pseudoplastic behaviour make it a component of water-based drilling fluids. This material 
is nontoxic and was approved by the FDA as a safe polymer in 1969, to be used in food 
products (Fed Reg 345376). With a backbone of β-1,4-D-glucopyranose glucan repeating 
units, it is a branched polymer with β-1,4 D-mannose, β-1,2 D-glucuronic acid and D-
mannose side chains (Figure 9). These trisaccharides are attached with α-1,3 linkages on 
each alternate glucose residue. While the mannose moiety in the terminal end is partially 
substituted with pyruvate residues linked to the 4- and 6-positions as an acetal in the side 
chain, the inner mannose unit undergoes acetylation at the C-6 position [207]. The charge 
density on the xanthan chain is increased when the deprotonation of O-acetyl and 
pyruvate residues take place at pH > 4.5, allowing physical crosslinking of the xanthan 
mediated by calcium ions. Xanthan has a polyanionic characteristic owing to the presence 
of glucuronic acid in the side chain [208]. 
  





Figure 9. Chemical structure of xanthan gum, (a) chair, and (b) Haworth projection [209]. 
Biosynthesis and Industrial Production 
The synthesis process of xanthan gum is similar to exopolysaccharide synthesis by 
other Gram-negative bacteria, using activated carbohydrate donors for shaping the 
polymer on the acceptor molecule. The biosynthesis is initiated through the Entner–
Doudoroff pathway transforming glucose to pyruvate [210]. Pyruvate then enters the 
tricarboxylic acid cycle to produce adenosine triphosphate (ATP) molecules. Other 
metabolic cycles follow, involving sugar donors (monosaccharides from nucleotide 
phosphor-sugars), sugar acceptors (polyprenol phosphate), acetyl-CoA, and 
phosphopyruvate, transferring sugar donors to the acceptors (lipid anchor) forming a 
sugar sequence [211]. The acetyl and pyruvyl residue enter the trisaccharide side chain 
and the latter influence the polymer viscosity (lesser the pyruvyl content, lower the 
viscosity). Industrial-grade xanthan is produced through fermentation followed by a 
pasteurization process to kill the microorganism, before precipitation in ethanol, spray 
drying, re-suspension in water, and re-precipitation [210]. Xanthan used for in vivo 
applications must progress through several enzymolysis and filtration processes to get an 
extremely pure version of the material [212]. In producing cell-free xanthan gum, the cell 
separation step is highly cost-intensive (though additions of alcohol and salt appear to 
promote precipitation) [213]. 
Biomedical Properties of Xanthan 
With a high molecular weight of 1–20 × 106 mol/g and intramolecular and 
intermolecular hydrogen bonding interactions due to the presence of the hydroxyl and 
carboxyl polar groups, xanthan exhibits a high intrinsic viscosity in an aqueous solution, 
even at low concentrations, behaving as a pseudoplastic fluid [209,213–215], explaining 
the use of xanthan in areas like food, cosmetics, and pharmaceuticals [216,217]. In a 
biomaterial context, improvement of xanthan’s existing properties such as solubility, 
swelling, gelation, or stability have (by hydroxy and carboxy group-mediated chemical 
modification) been considered. Additionally, the traditional drawbacks of xanthan 
including microbial contamination, uncontrolled hydration, low viscosity on storage, 
poor reactivity and thermal stability have been minimized through acetylation, 
esterification or etherification, oxidation, peptide linking, ionic and covalent crosslinking 
and other physical and mechanical modification [209]. At any concentration, xanthan fails 
to form a true gel due to weak, non-covalent intermolecular interactions [218]. However, 
hydrogel crosslinked 3D structures, produced using physical or chemical crosslinking, 
facilitates their use as a carrier of drugs or proteins in delivery systems [219]. 
Biocompatibility, non-toxicity, and softness of the material result in xanthan being 
suitable for this purpose [220]. 
One application of xanthan stems from its resistance to enzymatic digestion in the 
stomach or small intestine, providing a stabilising shield for an enclosed therapeutic factor 
and delivering them to the colon as they degrade in the presence of anaerobic microflora 
present in the colon [221]. Bacteroides, Bifidobacteria, and Eubacteria have been shown to 
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degrade xanthan for energy, making the (non-dysbiotic) colon environment an excellent 
end-point for a xanthan-based drug delivery system [222]. In a study based on acrylic 
acid-crosslinked xanthan and starch hydrogel grafts, crosslinked with acrylic acid 
maximum swelling capacity (caused by the ionization of –COOH groups to form –COO− 
ions) and prolonged release [223]. A xanthan nasal gel for drug delivery through the 
olfactory lobe helped improve drug permeation and bioavailability. The in-situ gel 
systems in ocular therapy resolve the difficulty in attaining optimal drug concentration, 
which is usually brought about by precorneal loss as an outcome of eye blinks and 
movements. Low molecular weight xanthan acts as an excellent anti-oxidant agent and 
protects against H2O2-injured Caco-2 cells, concurrently inhibiting oil peroxidation [224]. 
They also have an added benefit of immune protection against the neoplasm and 
resistance to overproduction of ROS, marking their importance as a potential anti-
inflammatory agent. Other xanthan-based carrier systems have included mucoadhesive 
nicotine-carrying patches with superior fast initial release and a subsequent controlled 
release for 10 h compared to contemporary patches [225]. Xanthan with chitosan was 
coated on liposomes assisting active protein delivery and exhibited an excellent drug 
release profile and mucoadhesive property [226]. The in vitro release study of 
zolmitriptan from xanthan, PVA, and HPMC film showed around 43% rapid release in 15 
min with no damage to the buccal mucosa [227]. The above examples clearly state its 
ability as a carrier of bioactive molecules and drugs mostly because of their stability, 
protection, and controlled release kinetics. 
Xanthan gum blended with natural-based polymers or materials like 
nanohydroxyapatite has been fabricated and assessed for bone, cartilage, skin 
regeneration, other tissue engineering applications, and cellular studies specified to its 
biomimicking potential [228]. Due to the very obvious biocompatibility and 
biodegradation, xanthan is an interesting material with huge potential as a tissue 
engineering scaffold. A significant proliferation of fibroblast tissues was shown when 
xanthan was fabricated with electroactive polypyrrole compared to virgin xanthan 
[229,230]. Chitosan and xanthan scaffolds also showed fibroblast viability as dermal 
dressing. The Xanthan hybrid scaffold with hydroxyapatite assisted in the cell adhesion 
and growth of osteoblasts, while improving alkaline phosphatase activity [228]. Xanthan 
in the presence of magnetic nanoparticles helped in vitro neural differentiation of stem 
cells [231]. Though contamination, viscosity variations, and thermal/mechanical 
instability are some of the impediments in their large-scale applications, its potential 
benefits can be exploited to push these limits to make them useful in the food industry 
and biomedical applications. 
2.1.7. Curdlan 
Curdlan is a high molecular weight extracellular polysaccharide composed of β-1,3 
glucopyranosyl repeating units connected by glycosidic linkage [232]. Discovered in 1966, 
Harada et al. [233] extracted the homoglycan from Alcaligenes faecalis var. myxogenes, 
observing the ability of the material to ‘curdle’ when heated. The resultant “curdlan” 
product was insoluble in water, with a temperature-initiated gelling property that forms 
elastic gels in an aqueous solution [234]. Curdlan is approved by the FDA for its safe use 
as a food additive and is a common source of dietary fibre in Korea, Taiwan, and Japan 
[235]. Curdlan biosynthesis is initiated when uridine diphosphate (UDP) glucose is 
synthesized from a carbohydrate substrate. The transfer of the monosaccharide from the 
precursor to the carrier lipid takes place and polymer construction is carried out 
subsequently. The formed polymer is extruded after chain elongation [236]. Curdlan is 
extracted on a commercial scale through the fermentation of Alcaligenes faecalis var. 
myxogenes, now reclassified as Agrobacterium sp. The material is extracted and thoroughly 
purified before use [237]. 
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Structure and Properties of Curdlan 
Curdlan comprises of β-(1,3)-glucans (Figure 10), a bacterial exopolysaccharide 
observed in both prokaryotes and eukaryotes. Curdlan can be considered significant 
among the β-(1,3)-glucans, due to their structural peculiarity, since they can be favourably 
manipulated. The solubility and rheological properties of curdlan therefore hold a special 
interest in biomedical material research [232]. 
 
Figure 10. Structure of β-(1,3)-glucans, curdlan. 
Unlike cellulose and chitin, curdlan is insoluble in water. However, organic solubility 
is much more enhanced compared to other materials in the same group—solubility in 
alkaline media is also preserved. Curdlan gelling behaviour is relatively novel in that it 
either forms a thermal non-reversible gel at around 80 °C or a thermally reversible gel at 
approximately 55 °C [238]. This interesting property is on account of its structural 
transformation when heated from room temperature to higher degrees [239]. At room 
temperature, curdlan has a single helical structure or triple helix that is loosely 
intertwined, which takes a more condensed and rod-like helical structural form with 
increasing temperature [240]. Recent literature has shed light on the immunostimulatory 
properties of β-glucans, where they are used as a biological response modifier. Modified 
curdlan (aminated or sulphated) as biological cues can enhance or adapt immune 
responses against tumours or for wound repair. The anti-infective and anti-inflammatory 
activities of curdlan enhance its scope in material application [241]. With such chemical 
derivatization accompanied by generic gelling and rheological properties and their 
commercial availability, curdlan can be considered as a material that imparts new 
properties for food and biomedical application. 
Biopharmaceutical Applications of Curdlan 
Curdlan is known for retaining its activities even after forming derivatives, especially 
carboxymethyl curdlan, which is extensively used to retain antitumor efficacy. In a recent 
study on the anti-infection property of curdlan, results confirmed resistance to 
colonization on E. coli in the intestine. The structural peculiarity and pharmacological 
capability of curdlan have found extended use in drug delivery [242]. Curdlan was used 
as an encapsulation vehicle in a rectal suppository system, where the gel stayed intact for 
slow drug diffusion [243]. In addition, Na et al. [244] demonstrated carboxymethylated 
curdlan-sulphonylurea copolymer nanoparticles encapsulating all-trans-retinoic acid, 
and showed first-order release kinetics with no cytotoxicity. All-trans retinoic acid is an 
active metabolite of vitamin A under the family retinoid. They have significant promise 
for cancer therapy and chemoprevention. 
Curdlan has also proved its importance in wound healing applications. Delatte et al. 
[245] improved healing speed, reduced pain, and lowered the number of dressing changes 
compared to standard treatments using a β-glucan collagen matrix, whilst curdlan 
blended with polyvinyl alcohol nanofiber scaffold crosslinked with glutaraldehyde 
vapour showed better wound closure data compared to the polyvinyl alcohol scaffold, 
probably due to the immunomodulatory properties of curdlan [246]. Despite sparse 
research on tissue engineering applications of curdlan, porous scaffolds developed with 
curdlan and polyvinyl alcohol foam have been reported, with results indicating 
Polymers 2021, 13, 1081 19 of 48 
 
 
favourable cell proliferation and differentiation in vivo, as well as preserving satisfactory 
enzymatic degradation [247]. 
Thus, curdlan shows great potential in biomedical applications. It has superior helical 
structural, pharmacological, and gelation properties and has not yet been explored to its 
full potential. The table summarizing polysaccharide production and biomedical 
applications can be found in Table 1. 
Table 1. Summary Table for Bacteria-Derived Polysaccharides. 
Polymer Polymer-Accumulating Bacteria Biomaterial Properties in Biomedical Application Ref. 
Dextran 
Leuconostoc sp., including L. 
pseudomesenteroides, L. mesenteroides 
and L. citreum 
Weisella cibaria, Wiesella confusa, 
Pediococcus pentosaceus, Lactobacillus 
satsumensis, and Lactobacillusplantarum 
Incorporation of dextran in drug delivery systems takes 
advantage of its structural integrity in forming 
hydrogels 
Dextran-drug conjugates enhance their analgesic and 
antipyretic properties whilst reducing their constituent 
drug’s ulcerogenic effect and also possess 
anticonvulsant properties 




Genera Streptomyces, Rhizobium, 
Methanococcus, Streptococcus, 
Enterobacter, Escherichia,  
Synechococcus, Micropruina and 
Candidatus 
Tissue engineering applications, as a crosslinker for 
hydrogels, allow for the generation of multifunctional 
and self-healing biomaterials 
Shown to increase elongation at break of polymer 
structures (at the expense of tensile strength)  
Controlled-release drug delivery has been trialled, 
especially in anti-cancer therapies 
[60–115] 
Alginate 
Wild-type Alginate Expressors 
include Pseudomonas aeruginosa and 
Azotobacter vinelandii 
Recombined into Escherichia coli 
Facilitate appropriate wound moisture retention and 
wound healing 
Excellent cell-adhesive and degradation behaviour 
Successfully used as a minimally invasive delivery 
system 
Exceptional sustained release and swelling degree 
Bind with divalent cations to form crosslinks and 





First commercial production in 
Streptococcus zooepidemicus 
Genera Streptococcus and Pasteurella 
Swelling ability has found use both in hydrogel tissue 
engineering research and in contemporary plastic 
surgery polymer expanding filling materials 
Synergistic lubricative ability has been trialled for the 
treatment of joint based pathology such as 
osteoarthritis 
HA is effective as an immunoisolation material, with 
avenues in type 1 diabetes treatment 
Natural affinity for some cancer surface proteins, such 
as CD44, promoting a drug delivery role 
[141–186] 
Gellan 
Sphingomonas elodea, Sphingomonas 
paucimobilis and Pseudomonas elodea 
Forms stable and self-supporting hydrogel and used as 
a culture media additive 
Generally used for oral formulations, as gels or coatings 
of capsules 
Protect bioactive molecules from the low pH 
[187–205] 
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Mostly applied in nasal, ocular, gastric pharmaceutical 
delivery systems, and as freeze-dried scaffold or 
sponges in tissue regeneration 
Xanthan 
Primarily expressed in Xanthamonas 
sp., Xantamonas campestris  
Resist enzymatic digestion in the stomach or small 
intestine encouraging in colon and stomach delivery 
systems 
Improved drug permeation and bioavailability with 
nasal gels 
Excellent biomimicking potential 
Potential biomolecules and therapeutic carriers because 




First extracted from Alcaligenes faecalis 
var. myxogenes, (later reclassified as 
Agrobacterium sp.) 
Used as a biological response modifier because of their 
immunostimulatory properties, anti-infective, and anti-
inflammatory 





Polyhydroxyalkanoates or PHAs were discovered by French microbiologist Maurice 
Lemoigne in 1926. He extracted the biopolymer within a bacterium called Bacillus 
megaterium that contained a short-chain-length PHA, poly(3-hydroxybutyrate) or P(3HB) 
[248]. PHA is a polyester, a polymer with linear ester linkages and differs in terms of the 
side pendant chain. The side chain is typically a saturated aliphatic chain with a range of 
carbon count of up to 13 carbons [249]. There were also variations in terms of the position 
of the pendant chain, such as 4-, 5-, and 6-hydroxyalkanoates, resulting in different 
polymer characteristics (Figure 11 and Table 2). These different polymer molecular 
structures are derived from different bacterial strains and species, as well as different 
carbon sources used, including fatty acids and sugar (Figure 12) [250]. 
 
Figure 11. The general chemical structure of PHAs. 
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Table 2. Examples of different aliphatic monomer side chains and the types of PHAs. 
x R Polymer Name Abbreviation Type 
1 methyl Poly-3-hydroxybutyrate P(3HB) scl 
 ethyl Poly-3-hydroxyvalerate P(3HV) scl 
 propyl Poly-3-hydroxyhexanoate P(3HHx) mcl 
 pentyl Poly-3-hydroxyoctanoate P(3HO) mcl 
 nonyl Poly-3-hydroxydodecanoate P(3HDD) lcl 
2 H Poly-4-hydroxybutyrate P(4HB) scl 
 methyl Poly-3-hydroxyvalerate P(4HV) scl 
3 H Poly-5-hydroxyvalerate P(5HV) scl 
 methyl Poly-5-hydroxyhexanoate P(5HHx) scl 
4 hexyl Poly-6-hydroxydodecanoate P(6HDD) mcl 
n = integer for repeating units. 




Figure 12. PHA biosynthetic pathways producing scl-PHAs and mcl-PHAs [251]. 
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Besides the chain variation, PHAs are not limited to homopolymer synthesis. Poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) or P(3HB-co-3HV) or PHBV [252,253], poly(3-
hydroxyhexanoate-co-3-hydroxyoctanoate) or P(3HHx-co-3HO) [254], poly(3-
hydroxybutyrate-co-3-hydroxyhexanoate) or P(3HB-co-3HHx) [255,256] and poly(3-
hydroxyoctanoate-co-3-hydroxydecanoate) or P(3HO-co-3HD) [257] are some examples of 
heteropolymeric PHAs, the distinctive structures of which are due to the low substrate 
specificity of the synthases, bacterial species, and carbon source utilised during the 
accumulation process [249]. Indeed, multiple types of bacteria have been utilised to obtain 
specific types of PHAs, such as Pseudomonas sp. [258] for mcl-PHA and Bacillus sp. [259] 
for scl-PHA production. Pseudomonas sp. has an added value in promoting sustainable 
PHA production since it is capable of feeding on readily available carbon substrates such 
as coconut oil [260], unprocessed biodiesel waste [261], and frying oil waste [262]. Certain 
microbes have been subjected to genetic modification in order to enable specific substrate 
uptake. For example, in an attempt to make the production of PHA cost-efficient, in 
Pseudomonas putida KT2440, the XylA and XylB genes have been introduced, which 
enabled xylose uptake as a sustainable alternative carbon source [263,264]. Another work 
modified P. putida KT2440 to overexpress PHA synthase genes promoting PHA 
accumulation, whilst deleting the depolymerase phaZ and β-oxidation genes to avoid 
PHA degradation [265]. 
PHA as a Biomaterial 
PHA utilisation in biomedical research is extensive due to its biocompatibility for a 
number of tissue types. Several aspects have been considered, including wound healing 
patches [266], bioresorbable sutures [267,268], drug delivery [269], as well as in scaffold 
development [257] for tissue engineering applications [270,271]. These applications 
mostly benefit from the elastomeric property of PHAs, especially mcl-PHAs [270,272,273]. 
Due to its biocompatibility and bioresorbability, PHA is actively involved in multiple 
research areas. 
Shishatskaya et al. [274] utilized poly(3-hydroxybutyrate-co-4-hydroxybutyrate) or 
P(3HB-co-4HB) copolymer films, noting the efficacy of the film in terms of reducing 
inflammation and promoting angiogenesis in the healing process. Meanwhile, the 
development of PHA-based sutures involving poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) or P(3HB-co-3HV) exhibited similarity in tissue healing response and 
were comparatively better, as compared to silk-based sutures in intramuscular 
implantation [268]. A more recent study developed a wound dressing material that 
incorporated antibiofilm proteins onto P(3HB-co-4HB) membranes, hindering bacterial 
infection on the wound surface [266]. Several modification attempts focusing on wound 
healing applications using a PHA blend with a synthetic polymer have also been explored 
[275], involving the enhancement of hydrophilicity, for e.g., a blend of polyvinyl alcohol 
with P(3HB) was used to produce electrospun fibre mats, which allowed proliferation of 
human keratinocytes and dermal fibroblasts [276]; introduction of antimicrobial groups; 
and polyethene glycol methacrylate (PEGMA) in poly-ε-caprolactone was blended with 
mcl-PHA through enzymatic functionalisation for a topical wound healing patch [277]. 
The combination of biocompatibility and good mechanical properties is ideal for a 
material to be considered as a tissue engineering material and PHAs have both. Following 
tailoring with appropriate processing techniques, PHA has been shown to facilitate cell 
seeding, adhesion, proliferation, differentiation, and de novo tissue regeneration [278]. In 
terms of providing physiological support, PHA is known as an excellent tissue scaffold 
(most notably for bone tissue engineering) [279]. PHBV-hydroxyapatite composites, for 
instance, have comparable physical and chemical similarities with human bones and serve 
as an excellent implant candidate for bone scaffolds [280,281]. Not limited to that, 
composite development of PHAs with bioglass also draws interest in the effort of 
perfecting the material for bone tissue engineering [282,283], as well as for PHA-
bioceramic composite for bone drug delivery [284]. 
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Besides bone tissue, PHAs have also been involved in several other types of tissue 
engineering scaffold development, especially in soft tissue engineering, including heart 
valves [285], blood vessel [286], tendon [287], and nerves [288]. Soft tissue engineering for 
cardiac muscle regeneration, developed using poly(3-hydroxyoctanoate), P(3HO), 
successfully mimic the mechanical properties of myocardial muscle and claimed to be as 
good as collagen, which furthers the potential of developing a cardiac patch [289]. In 
promoting nerve regeneration, PHAs have been used for the production of a 
bioresorbable conduit. This involved the blending of the crystalline P(3HB) and 
amorphous P(3HO). The blend percentage is specified—higher P(3HO) content had more 
correspondence to the peripheral nerves, especially for Young’s modulus and tensile 
strength [290]. The elastomeric property of PHAs is also useful in the effort of 
manufacturing matrix material for skin regeneration and wound healing. P(3HO) when 
combined with bioactive glass nanoparticles exhibited the ability to promote 
vascularization and exhibited antibacterial properties with enhanced hydrophilicity for 
skin tissue engineering [273]. Similar composite development strategies have 
demonstrated similar results but on using P(3HB) instead [291]. 
Another aspect in utilising PHA as a biomedical material is the development of a 
PHA-based drug delivery material. PHA was used to encapsulate a drug for controlled 
drug delivery, with the aim to adjust the material degradation rate over time to control 
the release kinetics of the compound [267,292,293]. In terms of encapsulation efficiency, 
the development of nanoparticles to encapsulate the anticancer drug, docetaxel, exploited 
the hydrophobicity of P(3HB) coupled with poly(lactide-co-glycolic) acid, or PLGA. The 
encapsulation efficiency increased when a higher percentage of PHB was used [294]. 
Antitumor drug rubomycin successfully promoted tumour inhibition when incorporated 
into P(3HB) microparticles [295]. Meanwhile, pioneering research involving the P(3HB-
co-3HV) copolymer used for the encapsulation of ellipticine, an antineoplastic drug, 
improved drug delivery efficiency two-fold compared to the non-encapsulated drug and 
exhibited improvement in terms of drug bioavailability at the site [296]. Additional 
research conjugated poly(2-dimethylaminoethyl methacrylate) and PHA to form 
thermosensitive and pH-sensitive copolymer constructs for the delivery of doxorubicin, 
an anticancer drug [297]. Hence, the biocompatibility of PHAs is widely acknowledged 
and exploited not only as neat polymers but as a part of more complex systems. In the 
future, it is hoped this family of polymers will have an extensive range of utilisation in 
tissue engineering and novel future drug development. 
2.2.2. Polylactic Acid 
Polylactic acid (PLA), or polylactide, is a widely known biopolymer consisting of 2-
hydroxypropionic acid or lactic acid repeating units. It is also a polyester consisting of L-
lactide and D-lactide, the stereoisomers of PLA. Depending on the type of isomers, three 
distinct kinds of PLA are known; poly(D-lactic acid) or PDLA, poly(L-lactic acid) or PLLA, 
and poly(D,L-lactic acid) or PDLLA (Figure 13) [298]. 
  
(a) (b) 





Figure 13. (a) PDLA, (b) PLLA, and (c) PDLLA, where n and m are integers of the repetition units. 
Polylactic Variant and Attributes 
Commonly, PLA is very brittle and strongly hydrophobic [298]. However, the 
physical and chemical properties of PLA are also defined by stereoisomeric monomer 
variation, which was decided based on the isomeric input during synthesis. Optically 
active D-lactic acid gives a crystallinity characteristic to the polymer matrix; meanwhile, 
L-lactic acid contributes flexibility [299]. Hence, PDLA is crystalline; PLLA is 
semicrystalline; and interestingly PDLLA, the polylactic acid polymer with a mixture of 
both is amorphous in nature. The monomeric composition also defines the thermal 
properties of PLA, with PDLA and PLLA having a higher decomposition temperature 
compared to PDLLA. PLA is generally soluble in most organic solvents, but not in 
aliphatic hydrocarbons and alcohols [298]. 
Production of Polylactic Acid 
Whilst PLA itself is not a naturally occurring biopolymer, its monomeric components 
are found in abundance in nature, mainly produced by lactic acid bacteria, categorised 
under the Gram-positive bacteria order Lactobacillales that use carbohydrate-containing 
pyranose and furanose sugars as substrates. Hence, PLA production needs chemical 
synthesis, which involves synthetic pathways. The chemical synthesis of PLA demands 
high purity of the substrate, whereas lactic acid fermentation may lead to impure 
products, which then need further downstream processing [300]. Hence, generally, there 
are three steps involved in the synthesis PLA: (i) lactic acid production by microbes, (ii) 
lactic acid purification and production of its dimer (lactide), and (iii) polycondensation of 
lactides through ring-opening polymerisation [301]. 
Therefore, scientists have developed an alternative to allow the biosynthesis of PLA 
by carrying out metabolic engineering. Genetic engineering of E. coli by inserting the gene 
encoding propionate CoA transferase and PHA synthase allowed the recombinant 
organism to produce PLA from glucose, as conducted by [302]. The glucose molecule is 
broken down into pyruvic acid, later converted into lactate hydrolysed by lactate 
dehydrogenase. Then, it is converted to lactyl CoA by propionate CoA transferase and 
eventually polymerised by the PHA synthase to produce PLA (Figure 14) [303]. The work 
also interestingly observed the production of PHB-LA copolymer, poly(3-
hydroxybutyrate-co-lactic acid) by a similar E. coli mutant strain, by adding 3-hydroxy-
butyric acid as a co-feeding material [304]. 




Figure 14. A schematic presentation of the PLA production pathway by recombinant E. coli. 
Adapted with permission from a report by Jung and Lee [304]. Copyright © 2021, Elsevier. 
Polylactic Acid in Biomedical Application 
PLA is widely known for its potential in biomedical applications. It is an excellent 
candidate due to its tailorable biodegradability and biocompatibility. Since PLA is a 
polyester, the ester linkage within the polymer backbone can hydrolyse easily, even 
without enzymatic action [305]. Due to this degradability, PLA is bioresorbable, allowing 
the material to naturally disintegrate as the target site is healing [306]. This characteristic 
is useful and leads to the utilisation of the polymer in a wide range of applications, 
especially as scaffolds for tissue engineering application and bone fixation purposes. In 
addition, PLA is a prospective drug delivery material due to its tailorable porosity for 
controlled adsorption and drug release [307]. 
In the utilisation of PLA, monomer composition is crucial for the development of the 
polymer suitable for specific application. PDLLA is a less crystalline polymer and 
possesses an improved biodegradability for extensive applications in the biomedical area. 
For example, composite pins made partly of PDLLA were compared with hydroxyapatite 
pins that were commonly used in bone grafting, and the performance quality observed 
was similar [308]. On the other hand, PLLA, which has a higher rigidity, is preferable in 
bone fixture applications in the form of screws or scaffolds [309]. The rate of reabsorption 
is also relatively longer for more than four years to allow enough time for healing before 
complete resorption [310]. In another comparative study, the performance of 
bioresorbable PLLA was compared with a titanium fixture for rabbit mandibular fracture 
repair and the former showed similar results in terms of mechanical support and healing 
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[311]. PLA can also be modified to adapt to specific applications; for example, PLLA is 
typically blended with polyglycolic acid for a fixture device [311], and also with 
hydroxyapatite as a composite bone scaffold material [310]. 
PLA is also regarded as a potential functional material in drug delivery systems. 
Preparation of PLA-based drug delivery methods include emulsification, 
nanoprecipitation, salting-out, spray-drying, and stable dispersion to achieve nano- and 
microparticles [312]. Incorporation of PLA actually serves as a biodegradable component 
since it is the most common FDA-approved biopolymer in many drug delivery systems 
[307]. In order to enable a tailored application, a composite is favoured over a single-
material system. For instance, a specialised drug delivery component, D-α-tocopherol 
polyethene glycol 1000 succinate-polylactide with galactosamine, was developed for 
targeting liver cancer cells [313]. In another study, PLA-chitin blend microspheres were 
developed to carry proteins with tailorable degradation rate [314]. Meanwhile, brain 
targeted nano-carriers integrated with PLA, such as polyethene glycol/PLA with a 
lactoferrin conjugate, encouraged drug uptake by brain cells [315]. In addition, penetratin-
conjugate with similar polyethene glycol/PLA blends enhanced accumulation via 
endocytosis and direct translocation [316]. 
One major challenge in the PLA blending is the phase separation between PLA and 
the component of interest [307]. The immiscibility has disadvantages in collective physical 
integrity and low mechanical properties in terms of structural strength [317]. However, 
this situation nevertheless potentially opens up potentialities for exploring the chemistry 
and molecular interaction of PLA blends for effective composite production for more 
advanced and extended biomedical applications in the future. For example, an 
encapsulation strategy in drug delivery material development involving a PLA 
copolymer, PLGA, was successfully done using titanium dioxide-oleic acid (TiO2-OA) by 
thermally induced phase separation technique or TIPS to become a scaffold with drug 
release ability [318]. The table summarizing polyester production and biomedical 
applications can be found in Table 3. 
Table 3. Summary Table for Bacteria-Derived Polyesters. 
Polymer Polymer-Accumulating Bacteria Biomaterial Properties in Biomedical Application Ref. 
Polyhydroxyalkano
ates 
First isolated from Bacillus 
megaterium 
Multiple strains of Bacillus and 
Pseudomonas, including P. putida 
and B. aquamaris 
Several aspects have been considered, including 
wound healing patches by promoting angiogenesis in 
the healing process, bioresorbable sutures, and in 
drug delivery with a tailorable material degradation 
rate 
Useful in scaffold development for tissue engineering 
applications, which is biocompatible for a number of 
tissue types by facilitating cell seeding, adhesion, 




PLA monomeric components 
being synthesized by bacteria of 
the order Lactobacillales 
Genetically modified Escherichia 
coli 
PLA is bioresorbable, allowing the material to 
naturally disintegrate as the target site is healing 
Acts as a scaffold for tissue engineering application 
and bone fixation purposes 
Prospective drug delivery material due to its 








Polyamines are structurally similar to proteins and hence represent the products of 
the commonest metabolic processes in an organism and can also be commonly derived 
from bacterial fermentation. 
2.3.1. ε-Poly-L-Lysine 
The first polyamine to be discussed here is ε-poly-L-lysine, or ε-PL. Despite lysine’s 
initial isolation from milk in 1889 [319], lysine in its polymeric form was not discovered 
until 1977, when Shima and Sakai [320] announced their discovery of what they called the 
“lysine polymer”, isolated from the culture filtrate of a bacterial strain similar to Strepto-
myces albulus [320,321]. This alkaloid polymer structure is characterised by the L-chirality 
of the constituent amino acid and by the position of the peptide bond, connecting lysine’s 
carboxylic acid group, and its ε-amine group (Figure 15) [321,322]. However, despite their 
successful identification of this novel biopolymer, Shima and Sakai [320] could not deter-
mine the physiological function of ε-PL, though contemporary research has now sug-
gested that ε-PL confers antimicrobial and acid-stress protection in ε-PL accumulating 
genera [323]. Nevertheless, humans have used its chemical, physical, and biological prop-
erties for a range of diverse applications in the intervening decades. 
 
Figure 15. The polymeric structure of ε-poly-L-lysine, where n is integer of the repetition units. 
Current Properties and Subsequent Applications 
The physicochemical properties of ε-PL make it well suited to both food industry-
related and biomedical applications. Shima and Sakai [320] determined that ε-PL is 
strongly cationic in solution, owing to the presence of a functional amine group. In fact, 
[324] proposes ε-PL as a cationic antimicrobial peptide. Cationic materials generate anti-
microbial effects due to their interactions with the anionic bacterial membrane, allowing 
penetration into the bacterial lipid membrane. After a certain threshold concentration is 
reached, lipid solubilization initiates the break-up of the cell [325]. This property has been 
confirmed in vitro against E. coli and Listeria innocua, leading to the inclusion of epsilon 
poly-L-lysine in a number of studies investigating antimicrobial biomaterials [326]. Xu et 
al. [327] successfully used ε-PL as an antimicrobial paint against E. coli and Methicillin 
Resistant Staphylococcus aureus (MRSA), reducing bacterial load on titanium surfaces im-
planted into a rodent model by up to Log 3. Moreover, multiple studies have incorporated 
their ε-PL into hydrogel networks, allowing for flexible, therapeutic factor or cell-loaded 
antimicrobial materials with self-healing capability [328,329]. Given this unique set of 
chemical and biological properties, ε-PL has been proposed as a novel antimicrobial 
wound dressing. Yang et al. [330] combined the antimicrobial properties of silver, chitosan 
(another cationic polymer), and ε-PL to generate highly biocompatible wound dressings 
capable of maintaining tissue bed moisture, excellent hygroscopicity, and antimicrobial 
activity against E. coli and S. aureus. Although no clinical trials have taken place yet fea-
turing wound dressings impregnated with ε-PL, its antimicrobial properties against both 
Gram-positive and Gram-negative bacteria, as well as its biocompatibility for wound 
dressing applications, could lead to novel dressings for the treatment of infected wounds. 
Although ε-PL is a polymer, its relatively limited chain length (25–35 amino acid res-
idues) has implications on its physical properties [331]. Despite sparse literature on me-
chanical properties, the medical applications it is involved in would indicate they are un-
suitable for high-strength applications. Indeed, attempts to construct polyglutamic acid 
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(PGA)/ε-PL films for probiotic packaging resulted in decreased construct tensile strength 
with increasing ε-PL, beyond 2 wt% of ε-PL, despite the elasticity of the developed mate-
rial greatly increasing with wt% ε-PL [331]. Conversely, research conducted on strongly 
adhesive mussel foot proteins (Mfps) found that many of the proteins contain (amongst 
other amino acids) lysine residues. These mfps can adhere to wet, polar surfaces through 
covalent bond formation, metal chelation, and water displacement, which makes them 
suitable for applications such as wound adhesives and dressings (Figure 16) [332]. 
 
Figure 16. (a) Diagram of mussel attachment, polylysine is contained with the plaque; (b) the primary amino acid sequence 
of mfp-5; (c) Conjugation of dopamine onto the mfp-5 mimetic polymer; (d) Horseradish Peroxidase (HRP) crosslinking 
of the polymer to form a hydrogel; and (e) application of polymer onto a mouse wound model. Used with permission 
from a report by Wang et al. [333] © 2021 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
Li et al. [334] constructed Mfp-inspired ε-poly-L-lysine adhesives that were able to 
resist 100 KPa of shear force between the collagen sheets [334]. Liu et al. [335] demon-
strated the biomaterial applications of this adhesive, generating a ε-PL/HA, bioresorbable, 
antibiotic dressing as an alternative to fibrin glue-requiring dressings. Although hard tis-
sue engineering may be beyond the scope of biomaterials containing ε-poly-L-lysine as 
the bulk material, research suggests that both soft tissue engineering and mechanically 
stable materials with polymer coating are niche applications for this polymer. In addition, 
the antimicrobial and wound-healing biomaterial sectors are highly suitable applications 
for ε-PL. 
Though wound healing is one of the main applications of ε-poly-L-lysine, research 
has also focused on therapeutic gene and drug delivery. De Smedt et al. [336] discussed 
the importance of cationic polymers in DNA binding, explaining that cationic molecules 
encourage polyplex (small DNA strands) condensation, giving researchers a stable gene 
encapsulation platform. Biodegradable polyethene glycol/polyleucine/ε-PL micelles have 
been used to successfully transfect 293T kidney fibroblasts with a vector plasmid. Deng et 
al. [337] noted increased DNA condensation and complex stability enabled by the hydro-
phobic nature of the chosen polymer. Despite limited clinical trials, stable targeted factor 
delivery is preferred in cancer treatment, where the need to deliver potentially toxic chem-
icals, whilst mitigating healthy tissue necrosis, is paramount [338]. Guo et al. [339] devel-
oped a targeted system using ε-poly-L-lysine conjugated with a pH sensitive compound 
that detected the increased acidity of the tumour microenvironment. ε-PL ensures the sta-
bility of the system until it reaches its target, allowing maximum drug delivery with lim-
ited pathology [339]. The stability of ε-PL allows previously fragile cancer therapeutic 
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structures to survive more rigorous environments. El Assal et al. [340] preserved cancer 
hunting Natural Killer (NK) cells using ε-PL, where previous cryopreservation attempts 
using solely contemporary cryoprotectants caused significant cell death. Hence, the bio-
resorbable property and stabilising qualities of ε-poly-L-lysine have resulted in its appli-
cation in the fields of cancer and wound healing. 
Production of the Polymer by Bacteria 
Bacterially derived ε-poly-L-lysine has been used as a preservative for more than 15 
years, with ε-PL receiving its FDA “GRAS” rating in 2004 [341,342]. The industrial strain 
of Streptomyces albulus soil has advanced from its original soil isolate [320], The isolation 
of strains producing up to four times the original yield obtained in the 1977 study have 
been noted in literature [340,343]. Further gains have been made using “genome shuf-
fling”, a technique involving the fusion of bacterial protoplasts generating new genome 
combinations [344]. This was carried out by Li et al. [345] to almost double the existing 
yield of Streptomyces graminearus cultures. Induced mutation has also been trialled. Opti-
misations to the growth conditions are also ongoing. They noticed a yield-limiting rise in 
toxic ROS in the reaction vessel, supplemented their feedstock with astaxanthin, an anti-
oxidant blackcurrant derivative, increasing their yield by 30% [345,346]. A continuous 
problem with improvements to the Streptomyces sp. growth model has been the historical 
lack of data on the genes expressing ε-PL synthases, a problem which (exacerbated by a 
lack of ε-PL accumulating organisms) prevented genetic transfer into more industrially 
suited micro-organisms [321]. However, Yamanaka et al. [347] finally identified the first 
ε-PL synthase, a non-ribosomal peptide synthase, which was followed up by the first het-
erologous expression in another Streptomyces species (Streptomyces lividans). Moreover, 
until recently, ε-poly-L-lysine had only been reported in a few strains of Streptomyces sp. 
However, a recent study published in October 2020 by Samadlouie et al. [348] demon-
strated for the first time the manufacture of ε-PL in another genus, Lactobacillus [321]. 
Whilst strains of Lactobacillus delbrueckii only produced 200 ppm of ε-PL in its growth me-
dium, the future successful translocation of the ε-PL genes into more commonly cultured 
species may allow manufacture of ε-PL in higher yields. 
2.3.2. Poly-γ-Glutamate (γ-PGA) 
Similar to ε-poly-L-lysine, poly-γ-glutamate (γ-PGA) is classified as a homo polyam-
ide made up of the repeating subunits of one amino acid residue (glutamate in the case of 
PGA) [349]. A non-essential amino acid, glutamate can be synthesised de novo in 
(amongst others) glial cells, indicating its importance in physiological function like neu-
rotransmission [350]. More importantly, glutamate is harmlessly metabolized in the body 
during the TCA cycle [351]. However, both ε-PL and γ-PGA biopolymers are only bio-
resorbed when they contain residues in the L-conformation; the enantiomeric selectivity 
of their respective enzymes prevents metabolism of the D-conformation of the polymer 
[352]. 
Properties of γ-PGA 
Chemically γ-PGA and ε-PL have fairly similar structures. Like ε-PL, γ-PGA is an 
amino acid, with a carboxylic acid, amine, and an R group [353]. γ-PGA differs from ε-PL 
by the presence of another carboxylic acid group (Figure 17), decreasing both the pH of 
solutions containing γ-PGA in its protonated state and increasing water solubility of the 
salt (the acid form is insoluble in water due to its propensity to form hydrophobic alpha-
helices through intramolecular hydrogen bonding) [354]. This also affects γ-PGA’s charge 
whilst in solution; making it anionic [355]. γ-PGA’s anionic nature makes it generally non-
conducive to lipid membrane solubilisation. 
  




Figure 17. Molecular structure of γ-PGA (note the n number and similarity to nylon). 
However, its non-degradation under enzymatic attack makes it an attractive candi-
date as an antimicrobial biomaterial that is resistant to bacterial protease virulence factors. 
Su et al. [356] observed an increased killing capacity of common mouthwash compounds 
against E. coli, S. aureus, and P. aeruginosa, by over 30%, with the addition of γ-PGA. This 
was reconfirmed by the similar antimicrobial capacity of γ-PGA-conjugated contact lens 
materials by the same group. Research using photosensitisers for use in photodynamic 
therapy have also used γ-PGA as a stable release platform [356,357]. This approach was 
demonstrated by Sun et al. [358], who conjugated their electrospun γ-PGA with a 
5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin tetra (p-toluenesulfonate) 
(TMPyP) photosensitizer, eradicating S. aureus from infected mouse model wounds under 
red light (650 nm) irradiation. 
γ-PGA has also been noted for its biomodulator roles in wound healing. Bae et al. 
[359] proposed that unnecessary damage following wound formation is caused by im-
mune and tissue-specific matrix metalloproteinase secretion. As an inhibitor, the γ-PGA 
negated these destructive effects with γ-PGA indirectly increasing cell proliferation and 
matrix formation through inhibition of the hyaluronidase enzyme [359]. This beneficial 
pro-inflammatory effect was confirmed in skin wounds by Choi et al. [360], who con-
firmed that daily topical application of γ-PGA to rat wounds increased Transforming 
Growth Factor (TGF-β1) signalling, angiogenesis, and re-epithelialization, initiating faster 
healing compared to saline controls. Although inflammation (of which ROS release is a 
part) is observed in healthy wound healing, ROS associated cytotoxicity have long been 
identified as markers of chronic wounds [361]. γ-PGA’s ability to be cross-linked (both by 
radiation and by chemical cross-linking) [362] and water sorption has allowed its use as a 
stable-release hydrogel platform for ROS inhibiting factors [363,364]. Zhang et al. [364] 
successfully used chitosan/γ-PGA hydrogel blends loaded with ROS degrading superox-
ide dismutase enzyme for this purpose, whilst Stevanović et al. [365] conjugated γ-PGA 
with PLGA to form antioxidant nanoparticles, which increased the ROS scavenging po-
tential by twofold compared to control cells [364,365]. Pisani et al. [366] confirmed this 
stability, concluding that their chitosan/γ-PGA/adult fibroblast cell hydrogel bioink pro-
vided a good compromise between shear resistance (important keeping cells in the matrix) 
and shear thinning (which promotes printability and cell viability on printing). 
Given the drug delivery potential of hydrogels, it is not surprising that (like many of 
the polymers in this review) γ-PGA has been trialled for targeted cancer drug and gene 
delivery. Upadhyay et al. [367] used the hyaluronan-CD44 cancer sensing pathway to de-
velop HA/γ-PGA-derivative doxorubicin loaded polymer beads targeted to cancer cells. 
Despite cationic structures excellent binding properties with respect to nucleic acid-based 
structures like DNA and RNA, this strong electrostatic attraction prevents dissociation 
from carrier medium, promoting poor delivery efficiency. Liao et al. [368] were able to 
partially counteract this using anionic γ-PGA, with the result of increasing the unpacking 
efficiency of siRNA in the intracellular cytosol. The addition of anionic structures like γ-
PGA (with little penalty to complex formation) allows the production of drug delivery 
devices with improved carrier stability and delivery efficiency [368]. 
  
Polymers 2021, 13, 1081 31 of 48 
 
 
Manufacture of Poly-γ-Glutamate 
Although γ-PGA is known as an antibacterial biomaterial, its purpose in nature is 
quite the opposite. The bacterial γ-PGA capsule promotes immunoisolation of the bacteria 
from the host immune system, whilst increasing the cytotoxicity of lethal toxin, a virulence 
factor expressed by Bacillus anthracis, from which γ-PGA was first isolated [369,370]. For-
tunately, a number of alternative prokaryotic and eukaryotic genera, as collated by 
Candela and Fouet [371], are capable of γ-PGA biosynthesis. Indeed, commercial exploi-
tation of Bacillus subtilis began from the manufacture of the vegetable cheese “Natto”, 
where γ-PGA has been fermented from soybean since at least 1051 AD [372]. 
Given its use since ancient times, much work has been undertaken to determine the 
expression of genes, and operation of enzymes pertaining to γ-PGA manufacture. There 
are however some unknowns. Luo et al. [373] documents the use of the polyglutamate 
synthase enzyme complex in an ATP-independent reaction, as well as the role of enzymes 
that convert one enantiomer to another (for example D, L racemization) during the for-
mation of the γ-PGA chain. However, the study also notes that the exact mechanisms and 
enzymes behind this is currently unknown [373]. What is known however is that fermen-
tation is relatively easy to achieve; [374] reported initial 18-h fermentations at 39 °C for 18 
h under high (up to 90%) humidity, followed by a shorter, colder fermentation step during 
the stationary phase, controlling carbon, nitrogen, oxygen, and H+ availability to induce 
γ-PGA production. Variations in strain fermentation efficacy promote optimisations; in-
dustrial Bacillus amyloliquefaciens fermentations now produce more than 65 g/kg of culture 
media γ-PGA following 60 h fermentation time, whilst Bacillus licheniformis A14 strain 
newly isolated from marine sands was able to produce 37 g/kg of culture media after just 
24 h of fermentation, an increase in efficiency of 45% of the latter over the former [374,375]. 
Finally, genetic engineering has been employed to increase yield; Cai et al. [376] used gene 
deletion vectors to remove by-product biosynthetic enzymes and reduce enzymes con-
trolling γ-PGA degradation in B. amyloliquefaciens more than doubling their yield (though 
their insertion of another set of genes responsible for γ-PGA synthetase expression had 
the opposite effect) [375], whilst Cai et al. [376] overexpressed genes responsible for 
NADPH generation in B. licheniformis WX-02, finding that increasing the metabolic capac-
ity promoted transcription for two key γ-PGA synthetase genes. Taken together, these 
significant improvements in yield herald both advancements for the commercial exploi-
tation of γ-PGA in the food industry and the availability of γ-PGA for biomaterials re-
search and implementation. The table summarizing polyamide production and biomedi-
cal applications can be found in Table 4. 
Table 4. Summary Table for Bacteria-Derived Polyamides. 





Cationic properties make ε-poly-L-lysine and excellent 
antimicrobial biomaterial and DNA binding for future 
use in gene therapies 
Has successfully been used as an antibiotic coating on ti-
tanium implants 
Strongly adhesive properties have suggested ε-poly-L-ly-
sine’s role in adhesive wound healing dressings. 
[319–348] 
Poly-γ-glutamate 
Multiple strains of genus “Bacil-
lus”, including B. anthracis, B. 
subtilis, B. licheniformis and B. am-
yloliquefaciens 
B. subtilis is responsible for most 
commercial production.  
Proposed applications in antimicrobials due to its re-
sistance to protease virulence factors 
Has improved the bacterial killing capacity of existing 
and experimental antimicrobials 









Polyphosphate is an inorganic polymer, naturally occurring in a wide range of living 
organisms, including bacteria. It consists of repeated units of phosphate groups (Figure 
18). It was isolated in 1890 by Liebermann from Baker’s yeast cells, Saccharomyces cerevisiae, 
originally naming it metaphosphoric acid [377]. Inorganic polyphosphate is typically 
available in most cell lineages [378], as well as being available in cells as an energy source 
in the form of ATP. Polyphosphate kinase is the enzyme responsible for the production of 
inorganic polyphosphate by polymerising terminal phosphate from ATP [379,380]. 
There are several types of polyphosphates available in nature based on both chain 
length and molecular pattern. The length of a polyphosphate influences its behaviour in 
the physiological environment; short chain polyphosphate is acid-soluble, while longer 
chains are progressively less soluble [378]. This characteristic was discovered primarily 
through analysis of the plant [381] and yeast [382] derived polymer. Variance in polyphos-
phate residue length can range from between two to 10 residues for short chain polyphos-
phate, compared to 500 residues for the long-chain polymer [383]. Conversely, the molec-
ular pattern is usually readily available in a linear form (though tri, tetra, and hexa-cyclic 
forms have been reported) [384]. Hyperbranched polyphosphate does not naturally occur; 
this synthetic form of polyphosphate is produced mainly for potential drug delivery ve-
hicle research [385–387]. Analytical extraction from a microbial source is typically carried 
out initially using trichloroacetic acid or perchloric acid as a chaotropic agent for cell dis-
ruption, subsequently adding a strong base such as sodium perchlorate or sodium hy-
droxide to dissolve polyphosphate. Later, dissolved polyphosphate is recovered by alco-
hol or Ba2+ precipitation [382]. 
 
Figure 18. Basic molecular structure of polyphosphate, where n is the number of repeating units. 
Microbial Production of Polyphosphate 
Generally, the enzyme that is responsible for the synthesis of polyphosphate is poly-
phosphate kinase [388]. There are two types of polyphosphate kinases: polyphosphate ki-
nase 1 and 2 (PPK1 and PPK2). Prokaryote polyphosphate is typically accumulated intra-
cellularly by PPK1. For instance, PPK1 expression by E. coli catalyses the reversible poly-
phosphate synthesis by extracting terminal phosphate from ATP [389]. PPK2 differs in 
polyphosphate source, using either guanosine triphosphate (GTP) or ATP for polyphos-
phate synthesis [390]. Additionally, enzyme stimulation is mediated by polyphosphate, 
taking the polymer as a donor to commence different enzymatic processes akin to nucle-
oside diphosphate kinase. The process converts guanosine diphosphate (GDP) into GTP, 
as ascertained in the metabolic pathways of P. aeruginosa [390,391]. In eukaryotic cells such 
as S. cerevisiae, vacuolar transporter chaperone 4 (VT4) availability enables polymerisation 
of phosphates into polyphosphate and simultaneous transportation into the vacuole, as a 
reserve for homeostatic balance, including phosphate sequestering, chelating toxic metals, 
and source of phosphate for DNA replication [392]. 
Polyphosphate-producing strains such as Citrobacter freundii and Candidatus accumu-
libacter have also found roles in the removal of excess polyphosphates in wastewater sys-
tems. Genetic modification approaches upon the bacteria enable them to take part in en-
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hanced biological phosphorus removal (EBPR). The modification promotes high effi-
ciency of phosphate uptake and polymerisation in the activated sludge system, more than 
the amount of phosphate required for the bacterial growth [393,394]. 
Polyphosphate Role in Physiological Processes 
The recognition of polyphosphate as one of the critical molecules that affect metabolic 
pathways in mammalian cells opens up the potential of the development of unique phar-
maceutical and therapeutic material, especially related to cellular dysregulation. Cur-
rently, it is known as a metabolic fuel in transferring polyphosphate extracellularly to af-
fect intracellular pathways, and also amplifying mitochondrial ATP production [395]. On 
the other hand, long-chain polyphosphate also promotes antibacterial and antiviral activ-
ity by forming ionic bonds with free Mg2+ and Ca2+, suppressing bacterial and viral viabil-
ity [396]. The exhaustion of these cations has been shown to retard microbial growth ob-
served in Bacillus cereus [397] and S. aureus 196E [398]. Besides that, polyphosphate ability 
to maintain the structural integrity of proteins in their folding mechanism in the presence 
of stress has been acknowledged [392]. 
There are a number of physiological pathways that polyphosphate could possibly 
involve in targeting human cells. In physiological blood clotting mechanisms, long-
chained (more than 500 units) polyphosphate with more than 500 phosphate units in-
creases the sensitivity of the contact pathway by increasing the fibrin clot turbidity, whilst 
the shorter chain (less than 100 units) polymer accelerates the activation of factor V, which 
inhibits anti-coagulation pathways and promotes clotting [399–401]. Moreover, insoluble 
polyphosphate expressed on platelets has also been linked with the activation of coagula-
tion factor XII and thrombus formation in contact system activation [402]. Polyphosphate 
also expresses a morphogenic role in bone and cartilage tissue in terms of promoting 
growth and repair from damages [403]. Apatite or calcium phosphate is a building block 
of bone tissues in vertebrates, and as such requires a phosphate reservoir for bone mainte-
nance. The suggestion is that polyphosphate has an active part in the calcification process 
of bone [404], explaining the significant amount of both soluble and insoluble polyphos-
phates found in osteoblast-like cells [405,406]. Thus, inorganic polyphosphate has many 
biomedical applications. 
3. Conclusions 
This review has demonstrated the enormous potential of bacteria-derived polymers 
in biomedical applications. Advances in biochemical engineering methods for optimal bi-
oprocess development, genetic modification methodologies, and artificial selection of mi-
crobes are furthering the economic viability of the production of these polymers. Moreo-
ver, production of polymers via bacterial fermentation has added advantages, including 
increased purity, reduced risk of zoonotic infection transmission, the ability to modify 
feedstock to tune biopolymer properties, the exclusivity of manufacture via only recently 
determined enzymatic pathways in some microorganisms, and the repeatability of the 
properties of the manufactured natural polymer. For processes that remain less economi-
cally sustainable, the extraordinary variety and promising properties of these biopoly-
mers will certainly encourage in depth research to overcome this hurdle. Hence, bacteria-
derived polymers are certainly evolving towards emerging as a family of future sustaina-
ble biomedical materials with a huge potential in varied applications, including cancer 
therapy, wound healing, tissue engineering, medical device development, and drug de-
livery. 
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